Printer Friendly

Daiichi Sankyo to invest JPY15bn in acceleration of antibody drug conjugate portfolio.

M2 EQUITYBITES-April 28, 2017-Daiichi Sankyo to invest JPY15bn in acceleration of antibody drug conjugate portfolio

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Daiichi Sankyo Company, Limited, a Japan-based pharmaceutical company, announced yesterday that it is making an initial JPY15bn investment to optimise and enhance its manufacturing capabilities to support its growing antibody drug conjugate (ADC) pipeline.

The company's investment is intended to build new manufacturing lines and refurbish others at three of the company's manufacturing plants in Japan. The company says that these improvements will optimise and expand the production of fully synthesized ADCs and ensure a stable supply for future investigational and commercial use.

Katsumi Fujimoto, PhD, senior executive officer, head of Supply Chain Division, Daiichi Sankyo, said, 'This strategic investment will bolster our leadership and expertise in ADC manufacturing, as we apply our proprietary ADC technology to more than two dozen biologics in preclinical or early stage development. Our manufacturing capacities will more than triple by 2021, affording us greater flexibility for research and development, and strengthening our anticipated future commercial production.'

ADC's are a type of targeted cancer medicine that deliver cytotoxic chemotherapy directly to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Daiichi Sankyo Cancer Enterprise's ADC Franchise currently consists of six novel ADCs including DS-8201 and U3-1402 in phase 1 clinical development, as well as DS-7300, DS-1062 and two other ADCs with undisclosed targets in pre-clinical development.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Apr 28, 2017
Words:256
Previous Article:Alexion Pharmaceuticals reports Q1 2017 results.
Next Article:Addnode reports increased profit of SEK27.1m in Q1 2017.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters